Dallas and Houston Mesothelioma Attorney
Pericardial Mesothelioma Lawyer
A rare type of cancer called mesothelioma is caused by an exposure to asbestos and asbestos products. There are two forms of mesothelioma: benign and malignant, but mesothelioma is rarely benign. Therefore mesothelioma is usually referred to as the malignant state or as a tumor. As with other forms of cancer, malignant mesothelioma tumors will expand and spread to other parts of the body.
The 3 types of mesothelioma cells are epithelioid, sarcomatoid and mixed/biphasic.
Mesothelioma is a serious disease no matter what type you have. If you have been diagnosed with mesothelioma contact an experienced mesothelioma attorney from Crain-Lewis today.
The most common type of mesothelioma is Epithelioid, which represents about 50-70% of all reported cases of mesothelioma and has the highest probability for survival. This type of mesothelioma cell affects the coverings of the body organs. A rarer type of meosthelioma cell is the Sarcomatoid, which affects the muscles, bones, fat and cartilage. It is a more serious form of mesothelioma, but is usually found 7-20% of the time. The 3rd type of mesothelioma cell is a mixture of both types of mesothelioma cells and occurs about 20-35% of the time.
In addition to being 3 types of mesothelioma cells, there are 3 types of mesothelioma each affecting a different part of the body. The 3 types of mesothelioma are pleural mesothelioma, peritoneal mesothelioma, and pericardial mesothelioma.
It doesn’t matter which area of the body that mesothelioma affects, it is always deadly and you should contact a mesothelioma lawyer from Crain-Lewis to handle your case. Currently the survival rate for mesothelioma is approximately 1-5 years following the diagnosis of mesothelioma.
Mesothlioma is a horrible disease. Let a Dallas and Houston mesothelioma attorney help you obtain the financial compensation you deserve. Contact a mesothelioma attorney at the Dallas and Houston mesothelioma trial lawyers at 877-339-2889
สมัครสมาชิก:
ส่งความคิดเห็น (Atom)
ไม่มีความคิดเห็น:
แสดงความคิดเห็น